SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial - Report - MDSpire

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  • By

  • Lauren Averett Byers

  • Byoung Chul Cho

  • Alissa J. Cooper

  • Anne C. Chiang

  • Ji-Youn Han

  • Muhammad Furqan

  • Afshin Dowlati

  • Daniel Morgensztern

  • Kyriakos P. Papadopoulos

  • Noura J. Choudhury

  • María Vieito

  • Jair Bar

  • Joo-Hang Kim

  • Wallace Akerley

  • Tae Min Kim

  • Young-Chul Kim

  • Luis Paz-Ares

  • Myung-Ju Ahn

  • Hiroshi Yokouchi

  • Darius Meiman

  • Wijith Munasinghe

  • Oluwadamilola Ogunyankin

  • Nadine Jahchan

  • Song Wang

  • Cristiano Ferlini

  • Randy R. Robinson

  • Frederick J. Kohlhapp

  • Tammy Palenski

  • Guillermo Rivell

  • Pooja Hingorani

  • Sreenivasa Chandana

  • June 1, 2026

  • 0 min

Share

Clinical Report: Phase 1 Trial of ABBV-706 in Advanced Small Cell Lung Cancer

Overview

The phase 1 trial of ABBV-706 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors, particularly those with relapsed/refractory small cell lung cancer (SCLC), achieving an overall response rate (ORR) of 43.8% (60.9% in R/R SCLC).

Background

Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis, particularly in extensive-stage cases where the 5-year overall survival rate is approximately 12%. Current treatment options often lead to rapid disease progression, underscoring the urgent need for innovative therapies. ABBV-706, an antibody-drug conjugate targeting SEZ6, represents a promising approach to address this unmet need.

Data Highlights

{'Overall Response Rate (ORR)': '43.8% (overall), 60.9% (in R/R SCLC)'}

Key Findings

{'Overall Response Rate (ORR)': '43.8% (overall), 60.9% (in R/R SCLC)'}

Clinical Implications

The promising efficacy of ABBV-706 in relapsed/refractory SCLC suggests it may serve as a valuable treatment option for patients who have limited alternatives. Clinicians should consider the potential of SEZ6-targeting therapies in their treatment strategies for advanced SCLC.

Conclusion

ABBV-706 shows significant promise as a novel therapeutic agent for patients with advanced SCLC, warranting further investigation in larger clinical trials to confirm its efficacy and safety.

Related Resources & Content

  1. The ASCO Post, HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors, 2025 -- HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors
  2. The ASCO Post, EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors, 2024 -- EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors
  3. The ASCO Post, Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer, 2017 -- Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer
  4. The ASCO Post, Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer, 2015 -- Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer
  5. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide, Journal of Clinical Oncology -- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide
  6. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer, FDA -- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
  7. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas, PubMed -- Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas
  8. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) | Journal of Clinical Oncology
  9. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer | FDA
  10. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas - PubMed

Original Source(s)

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  • by Lauren Averett Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji-Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, María Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young-Chul Kim, Luis Paz-Ares, Myung-Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy R. Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana

  • June 1, 2026

Related Content

Lung Cancer Screening Prevalence and Changes in 2024

Clinical efficacy and safety of porcine fibrin sealant in video-assisted thoracoscopic surgery lobectomy for lung cancer

Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer